Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Evommune went public late last year and is taking on stiff competition in immunology with a recent mid-stage clinical win.

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re ...

PSC Biotech partners with Blue Ocean Robotics to distribute the UVD Robot Pharma delivering autonomous UV C disinfection for ...